Research programme: prostate cancer therapy - Lynx/UroGene
Alternative Names: Prostate cancer therapy research programme - Lynx/UroGeneLatest Information Update: 16 Sep 2004
At a glance
- Originator Lynx Therapeutics; UroGene
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 16 Sep 2004 Discontinued - Preclinical for Prostate cancer in France (unspecified route)
- 16 Sep 2004 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 27 Mar 2001 Preclinical development for Prostate cancer in France (Unknown route)